Loading clinical trials...

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | Clinical Trials | Clareo Health

RECRUITINGPHASE3

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant

NCT06832410•Vertex Pharmaceuticals Incorporated

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
•Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
•Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study

Exclusion Criteria

•Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
•Participants had \>1 kidney transplant procedure

Locations (7)

Perelman Center for Advanced Medicine - Endocrinology

Philadelphia, Pennsylvania, United States

Montefiore Clinical and Translational Research Center - Endocrinology

Pittsburgh, Pennsylvania, United States

UW University Hospital - Endocrinology

Madison, Wisconsin, United States

Toronto General Hospital - Endocrinology

Toronto, Canada

Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre

Vancouver, Canada

King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology

Riyadh, Saudi Arabia

King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology

Riyadh, Saudi Arabia

Key Dates

Start Date

March 31, 2025

Primary Completion Date

September 17, 2026

Completion Date

September 17, 2027

Last Updated

August 21, 2025

Enrollment

ESTIMATED participants

Conditions

Type 1 DiabetesKidney Transplant

Interventions

Biological/Vaccine

BIOLOGICAL

Contacts

Medical Information

CONTACT

617-341-6777 medicalinfo@vrtx.com

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGEARLY_PHASE1

Pilot Trial of Supplemental Vitamin A and Nicotinamide

NCT05702398

Skin CancerKidney Transplant Recipients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Aerobic vs Resistance Exercise in Post-menopausal Women With Type 1 Diabetes

Dysautonomia in Children With Type 1 Diabetes

Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes

Parathyroidectomy After Kidney Transplantation